Fianlimab and Cemiplimab as Total Neoadjuvant Therapy (TNT) For Melanoma

University of California, Irvine

Summary

This is a phase II, open label clinical trial determining efficacy of Fianlimab in combination with Cemiplimab in subjects with Melanoma. These are subjects who will have surgery to remove their cancer.

Eligibility

Age range: Not specified
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * ≥18 years at the time of signing informed consent form (ICF) and able to independently complete informed consent. A certified translator must be used in the completion of informed consent for non-English speaking individuals. * Patients must have surgically resectable, macroscopic Stage IIIB-D cutaneous melanoma or oligometastatic resectable stage IV (M1a, M1b, and M1c) melanoma per American Joint Committee on Cancer 8th Edition Staging Criteria. Patients are eligible at the time of the initial diagnosis or recurrence after previous surgery. Patients should have \> 1 REC…

Interventions

Drug
Fianlimab
Given IV
Drug
Cemiplimab
Given IV

Location

Chao Family Comprehensive Cancer Center University of California, Irvine
Orange, California

Fianlimab and Cemiplimab as Total Neoadjuvant Therapy (TNT) For Melanoma

Summary

Eligibility

Interventions

Location

Compensation

Run this study?

Details

Conditions